Hester Biosciences Past Earnings Performance
Past criteria checks 1/6
Hester Biosciences's earnings have been declining at an average annual rate of -8.5%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 12.1% per year. Hester Biosciences's return on equity is 7%, and it has net margins of 6.2%.
Key information
-8.5%
Earnings growth rate
-7.8%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 12.1% |
| Return on equity | 7.0% |
| Net Margin | 6.2% |
| Next Earnings Update | 30 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hester Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2,992 | 185 | 740 | 0 |
| 30 Sep 23 | 3,106 | 257 | 730 | 0 |
| 30 Jun 23 | 3,164 | 285 | 602 | 0 |
| 31 Mar 23 | 2,782 | 266 | 675 | 0 |
| 31 Dec 22 | 2,723 | 298 | 621 | 0 |
| 30 Sep 22 | 2,514 | 271 | 581 | 0 |
| 30 Jun 22 | 2,379 | 308 | 541 | 0 |
| 31 Mar 22 | 2,466 | 393 | 536 | 0 |
| 31 Dec 21 | 2,504 | 413 | 519 | 0 |
| 30 Sep 21 | 2,501 | 451 | 520 | 0 |
| 30 Jun 21 | 2,397 | 412 | 493 | 0 |
| 31 Mar 21 | 2,177 | 344 | 447 | 0 |
| 31 Dec 20 | 1,989 | 275 | 403 | 0 |
| 30 Sep 20 | 1,917 | 267 | 397 | 0 |
| 30 Jun 20 | 1,848 | 265 | 406 | 0 |
| 31 Mar 20 | 1,878 | 292 | 538 | 0 |
| 31 Dec 19 | 1,956 | 396 | 364 | 0 |
| 30 Sep 19 | 1,906 | 409 | 334 | 0 |
| 30 Jun 19 | 1,890 | 413 | 308 | 0 |
| 31 Mar 19 | 1,842 | 416 | 289 | 0 |
| 31 Mar 18 | 1,373 | 256 | 244 | 0 |
| 31 Mar 17 | 1,232 | 235 | 189 | 0 |
| 31 Mar 16 | 1,009 | 192 | 156 | 0 |
| 31 Mar 15 | 900 | 136 | 135 | 0 |
| 31 Mar 14 | 690 | 95 | 203 | 13 |
Quality Earnings: 524669 has high quality earnings.
Growing Profit Margin: 524669's current net profit margins (6.2%) are lower than last year (11%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524669's earnings have declined by 8.5% per year over the past 5 years.
Accelerating Growth: 524669's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 524669 had negative earnings growth (-38.1%) over the past year, making it difficult to compare to the Biotechs industry average (-2.9%).
Return on Equity
High ROE: 524669's Return on Equity (7%) is considered low.